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The California Initiative embodied in Proposition 71 was designed to boost embryonic stem cell 
research and its translation into cell therapies in the face of federal restrictions on such research. 
With funding starting to flow, the stem cell revolution is now underway.A Bold Beginning
In 2004, California voters passed a bal-
lot initiative providing $3 billion in state 
monies over 10 years to support stem 
cell research carried out in California 
and to construct facilities to allow this 
research to take place unencumbered 
by federal restrictions. Born from the 
frustration of parents who recognized 
that the potential of stem cell therapy 
was being snuffed out by restrictive 
federal policies, Proposition 71 (The 
Stem Cell Research and Cures Initia-
tive) was designed around the scientific 
needs of researchers, physicians, and 
academic administrators with the goal 
of using state bond financing to gener-
ate long-term, stable capital support for 
human embryonic stem cell research 
and its translation into cell therapies. 
Proposition 71 was a courageous ini-
tiative at a time of opposition by the 
Bush Administration to such research 
and was also a milestone demonstrat-
ing that ordinary citizens are willing to 
take bold steps when Washington fails 
to meet its obligations.
Delays and Challenges
The California Institute for Regenera-
tive Medicine (CIRM) was established 
by Proposition 71 to distribute the grant 
monies. However, grant distribution was 
held up for 16 months while opponents 
of human embryonic stem cell research 
hamstrung the Institute in the courts, 
claiming the ballot initiative was uncon-
stitutional. During this time CIRM main-
tained momentum by donations from 
private philanthropists, followed by a 
life-giving loan of $150 million from Cali-
fornia Governor Arnold Schwarzenegger 522 Cell 132, February 22, 2008 ©2008 Else2 days after President Bush vetoed the 
bill that would have loosened restric-
tions on federal funds for embryonic 
stem cell research in the United States. 
Now, a mere 3 years after Proposition 
71’s approval, the court challenges have 
been overcome, the funding is flowing, 
and Californians have begun to see their 
vision realized.
Throughout the legal delays, vital 
infrastructure was built up by CIRM’s 
governing body, the 29-member Inde-
pendent Citizens’ Oversight Committee 
(ICOC), established by Proposition 71 
to include patient advocates, research 
institutes, and the business and general 
community of California to act in public 
to govern and to award grants recom-
mended by management. They estab-
lished operating procedures and created 
committees to establish working groups 
to oversee grants, standards, facilities, 
medical ethics, conflicts of interest, 
governance, and intellectual property. 
CIRM’s first President, Zach Hall, aided 
by Arlene Chiu, both veteran neuroscien-
tists with NIH administrative experience, 
hired a talented and committed staff, 
spearheaded a visionary strategic plan, 
and established procedures for issuing 
research funding applications (RFAs) 
and processes for managing the grants. 
Concurrently, the ICOC selected a peer 
review group comprised of expert scien-
tists from outside California, chaired by 
Harvard University’s Stuart Orkin.
Driving Research Forward
In 2006, CIRM’s funding apparatus 
finally began turning its gears, issuing a 
call for RFAs from new and established 
researchers investigating fundamental vier Inc.questions about embryonic stem cell 
biology. A total of $45 million over 2 to 
4 years has been awarded to 72 appli-
cants. In addition, a stem cell training 
program was established in which $40 
million was awarded for 3 years to cover 
the salaries of 54 graduate students, 80 
postdoctoral fellows, and 35 clinical fel-
lows, all of whom, as part of their train-
ing, are required to be schooled in the 
ethics of working with human stem cells. 
An additional $50 million was divided 
among 17 California institutions to con-
struct shared research facilities where 
investigators can work together, and six 
institutions received funding to teach 
courses in stem cell techniques to sci-
entists.
CIRM has recently announced addi-
tional programs to expand its research 
scope. For example, a competition has 
just been completed that provides gen-
erous 5-year young investigator grants 
for salary and operations to 22 assis-
tant professors. For the six clinician-
scientists successful in that competi-
tion, additional funds will be provided to 
repay their medical school tuition loans 
to encourage them to consider stem 
cell-related research as a viable career 
opportunity. A second round of new 
investigator grants targeting 14 or more 
investigators has been approved and will 
be evaluated in the coming months.
CIRM has also issued an RFA for 
establishing new pluripotent human 
stem cell lines and for new technologies 
to create them. We are interested in a 
multipronged approach that will include 
parallel lines of research not only on 
human embryonic stem cells but also on 
somatic cell reprogramming and induced 
pluripotency (Lewitzky and Yamanaka, 
2007). Human embryonic stem cells will 
remain the gold standard for character-
izing innate pluripotency, despite claims 
to the contrary expressed by President 
Bush in his State of the Union address 
last month.
Strengthening Research Facilities
CIRM panels are judging a $262 million 
funding competition for the construction 
of major research facilities in California. 
Twelve academic institutions that suc-
cessfully negotiated a scientific review 
are moving forward to qualify for desig-
nation as either CIRM “Institutes,” which 
will carry out basic, preclinical, and clini-
cal research; CIRM “Centres of Excel-
lence,” which will focus on two of those 
three areas; or CIRM “Special Programs,” 
which will focus on one of the three pro-
grams. A requirement for matching funds 
from the candidate institutions will lever-
age CIRM’s contribution considerably, 
with over $700 million expected to flow 
into the program from all sources.
CIRM-funded “Institutes” will house, 
at one location, basic researchers, 
translational scientists, and clinicians 
who will also maintain links with col-
leagues within and between institutions 
in various regions of California. Califor-
nia institutions are already drawing key 
scientists from around the country as 
well as from overseas: among others, 
Martin Pera to the University of Southern 
California, Peter Donovan to UC Irvine, 
Stephan Heller to Stanford, and Nissan 
Benvenisty to Cedars-Sinai. In addition, 
James Thomson and Shinya Yamanaka 
have agreed to spend part of their time 
at UC Santa Barbara and the Gladstone 
Institute, respectively. The influx of such 
top researchers will hopefully induce a 
new generation of young scientists to 
seek training and faculty appointments 
in California.
Eight other states in the US have 
commitments in process that total just 
under $2 billion for their own stem cell 
programs, in part to retain staff and to 
reduce emigration. We welcome their 
efforts, for increasing the number of 
stem cell researchers across the coun-
try stands to benefit all programs in the 
United States and to spur advances 
in stem cell research and cell therapy 
applications globally.Additional Funding Capacity
CIRM has also posted planning grants 
for Research Disease Teams to enable 
multidisciplinary teams of research-
ers in academia and business to write 
grants that integrate basic discoveries, 
translational research, and clinical trials 
for treating specific diseases or injuries 
with cell replacement therapy. Sup-
port for prospective planning grants is 
rarely provided by granting agencies, 
but this new program, by aligning basic 
and clinical research with the interests 
of for-profit companies, lies at the heart 
of CIRM’s mission to translate basic 
research into improved clinical care. It 
is vital that we marshal all aspects of 
California’s research capacity toward 
the development of stem cell therapeu-
tics. The 2008 Disease Team Research 
Grants will require identification of an 
investigational new drug (IND) target that 
can reasonably be reached within 4–5 
years, with funding potentially reaching 
$20 million (subject to ICOC approval), 
if all milestones are achieved through to 
phase II clinical trials.
A key goal of CIRM is to integrate for-
profit companies into its programs to lever 
and expand the capacity to generate cell 
therapeutics. For-profit companies are 
more experienced than nonprofits at see-
ing commercial opportunities, facilitating 
research by supplying laboratory reagents 
and materials, manufacturing cell prod-
ucts suitable for clinical use, understand-
ing the regulatory processes involved in 
translational medicine, and opening the 
cell product pipeline to clinical applica-
tion for patients. For this reason, the 
governing body of CIRM is investigating 
the possibility of allowing for-profit com-
panies to compete for financial support 
from CIRM in an ambitious revolving 
loan program. In the proposed program, 
the grants to for-profit companies will be 
paid back to CIRM on a basis to be deter-
mined and will be reinvested for further 
grant or loan support to accelerate stem 
cell research applications. This support 
from CIRM may be expected to attract 
additional leverage funding for for-profit 
companies from venture capital or other 
financial institutions. The ICOC has now 
established a Loan Task Force to seek the 
advice of California’s business, financing, 
and venture capital communities as to 
how such a program could work.Cell 132National and International  
Collaborations
CIRM is eager to support collaborations 
among CIRM-sponsored investigators 
and institutions and other stem cell pro-
grams in the US and globally. We would 
like to create joint funding initiatives that 
will link international efforts with our 
own, for example, to standardize expan-
sion, differentiation, and manufactur-
ing methods and to assess the variant 
properties of different stem cell lines 
that may define their stability and clinical 
usefulness. Discussions with Canada on 
cancer stem cell research collaborations 
are already underway, and initiatives 
have been proposed with Australia, UK, 
France, and others. These early-stage 
negotiations seek working relationships 
that include joint programs funded by all 
partners and consistency with CIRM val-
ues in award and grant policy. Bioinfor-
matics is another potential and valuable 
target for international collaborations 
and shared research findings.
CIRM plans to reach out to our national 
and international colleagues by hosting 
meetings and encouraging exchanges, 
visits, and sabbaticals to promote the 
sharing of information, to expand the 
network, and to reduce duplication of 
effort. We will seek to broaden the man-
date to include all forms of science that 
will move the stem cell agenda forward, 
including, for example, an emphasis on 
immunology, which will be key for clini-
cal applications. In sum, CIRM will work 
to dissolve any barriers that delay prog-
ress toward clinical applications. Mature 
programs of research, translation, and 
clinical trials under way in other locations 
can only enhance the ability of Califor-
nia researchers to develop and deliver 
therapeutics. CIRM is open to building 
bridges to other public and philanthropic 
organizations and to exploring joint 
efforts where they can assist us in deliv-
ering CIRM’s mission for the Californian 
community.
The Road Ahead
CIRM’s future scientific programs will 
aim to maintain a wide range of inter-
ests, guided by the directions set by 
our grant applicants and by staff, who 
will be closely watching developments 
in all fields to identify needs and oppor-
tunities. For example, research propos-, February 22, 2008 ©2008 Elsevier Inc. 523
als on deriving new pluripotent stem 
cell lines including disease-specific cell 
lines, induced pluripotent stem (iPS) 
cells, parthenogenetic and androgenetic 
stem cells, and placental stem cells have 
all been identified as potential areas to 
be funded. We will not be restricted by 
political conflicts that aim to separate 
research efforts on embryonic stem 
cells, fetal and placental stem cells, 
and adult tissue stem cells. We believe 
such distinctions are potential barriers to 
developing safe and effective therapies. 
In actuality, the fields overlap, as evi-
denced by the fact that derivation of iPS 
cells from adult somatic cells is based 
on information from expression profiling 
of embryonic stem cells. The identifica-
tion of directed differentiation pathways 
and the growth factors, cytokines, and 
inducers necessary to yield specific cell 
types for therapy will also depend on 
data gathered from human embryonic 
stem cells. The clinical response of the 
body to cells introduced to repair dam-
aged tissue will require the experience 
obtained from autologous and allogeneic 
transplantation. For these and other rea-
sons, integrating the entire spectrum of 
stem cell experiences appears sensible 
and productive.524 Cell 132, February 22, 2008 ©2008 ElseThere will be particular emphasis on 
immunology as many diseases, such 
as multiple sclerosis and juvenile dia-
betes, include an autoimmune com-
ponent that will require manipulation 
of the immune system before tissue 
repair with exogenous stem cell popu-
lations can be attempted. Strategies 
that involve reinstruction of tolerance 
and removal of activated immune cells 
may need to precede reintroduction of 
the target cells. This could involve che-
motherapies, thymic stimulation, adult 
stem cell therapy (hematopoietic and/
or mesenchymal stem cells), and even-
tually transplantation of progenitor cell 
types derived from pluripotent stem 
cells in culture. Autologous cell thera-
pies are likely to be more effective than 
allogeneic therapies, unless immuno-
logical interventions can be developed 
to ensure tolerance to the transplanted 
cells (Seach et al., 2007).
The road ahead leading to stem cell 
therapies and possible cures may be 
long and arduous. But California has 
tremendous resources to apply to the 
problem, plus a populace that supports 
the effort. By April of this year, CIRM 
will have invested over $500 million in 
California, making it the world’s largest vier Inc.funder of embryonic stem cell research. 
Matching donor and institutional funding 
in California is expected to bring in an 
additional $550 million, bringing the total 
funding commitment to over $1 billion. 
By creating a critical mass of stem cell 
researchers as well as synergy among 
the rich public and private sector intel-
lectual assets, California will remain 
steadfast in its dedication to developing 
the stem cell therapies and cures that its 
citizens and patient families dreamed of 
when the community embraced Proposi-
tion 71. California’s funding together with 
its scientific and clinical talent will ensure 
a major impact on medical research for 
treating chronic disease and injury.
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